TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients.
TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients. J Immunol Res. 2019;2019:6728694 Authors: Ciccacci C, Latini A, Perricone C, Conigliaro P, Colafrancesco S, Ceccarelli F, Priori R, Conti F, Perricone R, Novelli G, Borgiani P Abstract Autoimmune diseases (AIDs) are complex diseases characterized by persistent or recurrent inflammation, alteration of immune response, and production of specific autoantibodies. It is known that different AIDs share several susceptibility genetic loci. Tumor necrosis factor alpha inducible protein 3 (TNFAIP3) encodes the ubiquitin-modifying enzyme A20, which downregulates inflammation by restricting NF-κB, a transcription factor that regulates expression of various proinflammatory genes. Variants in TNFAIP3 gene have been described as associated with susceptibility to several AIDs. Here, we analyzed two TNFAIP3 polymorphisms in Italian patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjogren's syndrome (pSS), to verify if the genetic variability of TNFAIP3 gene is involved in genetic predisposition to AIDs also in the Italian population. We recruited 313 SLE patients, 256 RA patients, 195 pSS patients, and 236 healthy controls. Genotyping of rs2230926 and rs6920220 in TNFAIP3 gene was performed by an all...
ConclusionOur clinical outcomes are comparable overall to the three main published articles on this topic. The risk of infection and benefits of preventative fixation were apparent in our cohort.Level of evidenceIV, retrospective study.
This study focused on the expression of CD38 and HLA-DR on lymphocyte subsets in various groups of HIV-infected individuals and to determine their association with HIV-1 disease progression.MethodsNinety-eight cases of patients with HIV/AIDS in different disease stages and twenty-four healthy HIV-negative individuals were included in the cross-sectional study. Their immune function and abnormal immune activation markers (CD38 &HLA-DR) were detected using a flowcytometer, and HIV-1 RNA levels in individuals receiving antiretroviral drugs were estimated.ResultsThe immune activation marker levels were significantly differ...
Authors: Awasthi A, Kumar H PMID: 31608783 [PubMed - in process]
We report a 65-year-old female with non-Hodgkin’s lymphoma who developed native valve infective endocarditis due to Micrococcus luteus. There is no defined therapeutic regimen for infective endocarditis due to Micrococcus luteus; however, our patient was successfully treated for six weeks with vancomycin and rifampin. To our knowledge, there is only one other case report of native valve endocarditis due to Micrococcus luteus.
ConclusionsThe hypoglycemic mechanism of DOP might be associated with the regulation of glucagon-mediated hepatic glycogen metabolism and gluconeogenesis, and of liver glycogen structure, contributing to improved hepatic glucose metabolism in diabetic mice.Graphical abstractDOP could regulate glucagon-mediated signaling pathways and reverse the instability of liver glycogen structure, contributing to improved hepatic glucose metabolism.
Boston University researchers found that while effective in treating pain, cortisone jabs can speed up a joint's disintegration and force patients to have full knee or hip replacements.
ConclusionWhile radiation therapy might increase long-term toxicity in cHL, in our large data cohort, radiotherapy consolidation as part of the initial therapy for early stage disease provides superior survival at 10 years, especially in favorable risk cHL.
Publication date: Available online 14 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Sundar Jagannath, Robert M. Rifkin, Cristina J. Gasparetto, Kathleen Toomey, Brian G.M. Durie, James W. Hardin, Howard R. Terebelo, Lynne Wagner, Mohit Narang, Sikander Ailawadhi, James L. Omel, Shankar Srinivasan, Mia He, Brian Ung, Amani Kitali, E. Dawn Flick, Amit Agarwal, Rafat Abonour, CONNECT MM Registry InvestigatorsGraphical abstract
In conclusion, the triple combination of ATRA and ATO plus IDA as both an induction and consolidation therapy for the HR and SR groups attained excellent outcomes, and this regimen was effective, safe and easy, without maintenance therapy. The triple combination treatment might be a preferred frontline therapy for APL patients, especially for HR patients or patients with the APL FLT3-ITD mutation.
Publication date: Available online 13 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lindsay Wilde, Jonathan PanAbstractAnemia is the most common cytopenia seen in the myelodysplastic syndromes (MDS). The majority of patients with MDS will require red blood cell (RBC) transfusions during the course of their disease. However, unlike many other disease groups, there is no consensus on the optimal strategy for RBC transfusion in this patient population. In this article, we review the data supporting the use of restrictive transfusion strategies in multiple patient populations and discuss the current lite...